STEVENSON, Md., Dec. 18, 2017 -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of purchasers of Alkermes plc (Nasdaq:ALKS) (“Alkermes” or the “Company”) securities during the period between February 24, 2015 and November 3, 2017, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until January 22, 2018 to seek appointment as lead plaintiff.
If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in Alkermes securities during the Class Period. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action.
The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants’ failure to disclose during the Class Period that Alkermes systemically engaged in deceptive marketing campaigns to influence policymakers to use Vivitrol in addiction treatment programs over more scientifically proven and efficacious alternatives, which was not sustainable and which would foreseeably subject Alkermes to heightened regulatory and legislative scrutiny.
According to the complaint, following a June 11, 2017 article about the aggressive marketing efforts, and a November 6, 2017 announcement of an investigation into the Company’s sales practices, the value of Alkermes shares declined significantly
If you have suffered a loss in excess of $100,000 from investment in Alkermes securities purchased on or after February 24, 2015 and held through the revelation of negative information during and/or at the end of the Class Period and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please visit our website at http://www.browerpiven.com/casesandinvestigations.html. You may also request more information by contacting Brower Piven either by email at [email protected] or by telephone at (410) 415-6616.
Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s. If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.
CONTACT: Charles J. Piven
Brower Piven, A Professional Corporation
1925 Old Valley Road
Stevenson, Maryland 21153
Telephone: 410-415-6616
[email protected]


American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units
Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit
Samsung Electronics Shares Jump on HBM4 Mass Production Report
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks
Amazon Explores AI Content Marketplace With Media Publishers
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 



